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Abstract
Background: Roux-en-Y gastric bypass surgery is widely applied to ameliorate morbid obesity, including diabetes
in people with type 2 diabetes. The latter vanish a few days after surgery for many, but not in all patients before
any weight reduction has occurred. The explanation for this change in metabolic status is poorly understood, but
the observation may suggest that the fate obesity and diabetes is only partly linked after surgery.
Methods: The trajectories of weight reduction measured as reduced body mass index (BMI) in 741obese subjects
with and without diabetes were evaluated. Evaluation was performed on three groups: 1) subjects that were
non-diabetic before and after surgery; 2) subjects that were diabetics before surgery but non-diabetics after
surgery; and 3) subjects that were diabetics before surgery and remained diabetics after surgery. The diabetic
state was established at HbA1c above 48 mmol/mol.
Results: The trajectories differ significantly between groups and any sub-populations of groups, the latter identified by
the distance between individual trajectories using a k-means procedure. The results suggest that different domains in
the enormous genetic network governing basic metabolism are perturbed in obesity and diabetes, and in fact some of
the patients are affected by two distinct diseases: obesity and diabetes mellitus type 2.
Conclusion: Although RYGB “normalized” many glycaemic parameters in some of the diabetic subjects apparently
converting to a non-diabetics state, other diabetic subjects stay diabetic in the context of the new gut anatomy after
surgery. Thus, the obesity part of the glycaemic derangement may have been ameliorated, but some defects of the
diabetic state had not.
Background
Laparoscopic Roux-en-Y gastric bypass (RYGB) is an ef-
fective method for the treatment of patients with morbid
obesity and a number of studies have shown that RYGB
results in a permanent loss of up to 40 % of excess
weight [1, 2]. Up to one third of the operated obese sub-
jects present themselves with diabetes mellitus type 2
and RYGB is by far the most effective surgical procedure
to obtain remission of diabetes [3] maybe except for the
more radical bilio-pancreatic diversion operation [1, 3, 4].
RYGB improves glycaemic control in the diabetics already
a few days after the operation and before any weight
reduction has been obtained [5, 6]. The diabetic remission
rate is in the range of 40–80 % in part depending on the
definition of remission [1, 3, 7] and the duration of
diabetes prior to surgery. Similar results have been
presented for diabetic patients without severe obesity
[8–10]. Thus, the primary purpose of bariatric surgery
(as the name imply) was to reduce weight but has
now turned to be performed in the broader context
of “metabolic surgery” [2].
The main short-term mechanism behind the improve-
ment in glycaemic control is an increase in hepatic insu-
lin sensitivity induced by caloric restriction and an
improved beta-cell function, which is unrelated to
weight loss, but may be explained by the exaggerated
GLP-1 response after surgery [5, 11, 12]. In contrast, im-
proved peripheral (skeletal muscle) insulin sensitivity is
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strongly associated with weight loss [12–14]. However,
the relative importance of caloric restriction versus the
changes in gut hormone secretion for the remission of
diabetes is still discussed [15, 16]. GLP-1 has strong
insulinotropic effects and inhibits glucagon release and,
in complex interactions with glucose-dependent insuli-
notropic polypeptide (GIP), defines the much favoured
lower intestine hypothesis of diabetic remission. The
ghrelin hypothesis states that ghrelin secretion from the
stomach and proximal intestine is disturbed decreasing
appetite and fat mass, while the upper intestine (anti-
incretin) hypothesis suggests that some unknown factors
or processes in the duodenum influencing the glucose
homoeostasis and impaired in type2 diabetes are altered
by RYGB [2, 17]. These hypotheses including the effect
of calorie restriction may not be exclusive, but for now
the exact physiology behind the remission of diabetes in
some but not all patients remains elusive.
In the present contribution we evaluated the trajec-
tories of weight reduction measured as reduction in
body mass index (BMI) applying information theoretic
approaches to RYGB-treated obese patients with and
without diabetes. Although the mechanism(s) of the
vanishing of diabetes is far from resolved our results
suggest that different domains of the genetics network
governing the basic metabolic processes leading to
obesity and diabetes are perturbed in these heteroge-
neous conditions. Obesity is considered a risk factor
for developing diabetes, but the link may be quite
vague, as only 30 % of our morbid obese patients do
present themselves with diabetes. In addition both
conditions are polygenic in nature and are therefore
heterogeneous entities considering the vast number of
genetic mutations detected in human genome [18].
Methods
Population
The subjects included in the study have all been
treated by gastric bypass surgery for severe obesity
(bariatric surgery). A total population of 1189 subjects, all
of Caucasian ethnicity, have been described and moni-
tored clinically and para-clinically from June 2009 to
November 2014. Surgery was performed using a stand-
ard laparoscopic RYGB technique creating a 25 ml gas-
tric pouch a 75 cm long bilio-pancreatic limb and a
100 cm long Roux limb as previously described [19].
Blood, serum, plasma and urine were obtained at each
(pre- and postsurgical) visit to the clinic and amounts to
more than 2500 serum/plasma and urine sample. Full
records are available for 741 patients in whom laparo-
scopic “Roux-en-Y gastric bypass” (RYGB) were per-
formed and forms the core in this contribution. The
follow-up time after surgery was 22.6 month on average
(range 3–77 months).
The population was divided in three sub-populations
before surgery: 1) a sub-population which were non-
diabetic before and after surgery; 2) a diabetic sub-
population defined purely by the relative concentration
of glycated haemoglobin (HbA1c) according to the IFCC
standard (HbA1c >48 mmol/mol) at any time (glycaemic
diabetics); and 3) a diabetic sub-population with HbA1c
below the cut-off levels at all time, but treated with anti-
diabetic agents (treatment diabetics). The rational for
this distinction between diabetic patients, is that patients
with HbA1c above the cut-off level regardless of treat-
ment genuinely are diabetics by definition. Treated pa-
tients (anti-diabetic drugs or insulin) with levels below
the cut-off at all times may have been diabetics before
surgery but turned non-diabetic due to weight loss but
were still treated with anti-diabetic drugs. The glycaemic
diabetic sub-population was further divided into two
subgroups, one that converted to non-diabetics post-
surgery without any anti-diabetic treatment, and a sub-
group receiving anti-diabetic agents.
The glycaemic status was not determined in 6 RYGB-
patients who were excluded from further analysis.
Biochemical analysis
The HbA1c level was determined by liquid chromatog-
raphy (Tosoh, Alere, Belgium) in a standard setup used
for routine clinical diagnostics. Haemoglobin and blood
cell counts were performed on SysMex 500 (Sysmex,
Japan) using standard protocols. INR analysis and calcu-
lation were performed by ACL TOP (IL, Italy). All other
variables were analysed on Cobas 6000 (Roche Hitashi,
Japan). All analyses were performed using the standard
protocols as recommended by the manufactures used for
routine clinical diagnostics. All analyses were performed
the day of sampling.
The homoeostases model assessment [20] was used to
estimate insulin resistance (HOMA-IR) and pancreatic
β-cell function (HOMA-beta).
Basic data analysis
Relative changes in variables were calculated as the
minimal post-surgery value compared to the latest
pre-surgery value. If a variable increased post-surgery
the changes are shown as negative values. Variables
for which no changes after surgery were observed
were excluded from further analysis as they were
non-informative for the physiological processes related
to obesity and diabetes. The pre- and post-surgery
values as well as the relative changes were pooled in
each sub-population and for both gender separately
for all traits. The cumulative distributions of the traits
were compared pair-wise by the Kolmogorov-Smirnov
two-sample test as implemented in http://scipy.org/.
This is a non-parametric test of two empirical samples of
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continuous variables defining the largest absolute differ-
ence between the two cumulative distributions. The test is
symmetric, do not require equal sample size and generates
a p-value for significance. Increasing test-statistics (and
hence decreasing p-values) indicate increasing dissimilar-
ity of distributions and hence weaker correlation. The idea
of these analyses is that traits should have similar distribu-
tions (of any kind) to be correlated, and the more similar
they are the closer the interactions of the traits.
Classification of sub-populations
The sub-populations are supposedly heterogeneous [18],
and were disentangled into classes using a k-means pro-
cedure. For the purpose of analysis of the structure of
the population the data from each gender were pooled
as in the vast majority of traits no gender difference
were detected (Additional file 1: Table S1). The time-
series data used for classification were normalized BMI
(normalized to the pre-surgery value).
The time series for each subject in each sub-
population were fitted to polynomials of increasing de-
gree using the polyfit and polyval functions in numpy
(http://scipy.org/). The polynomial degree with the low-
est Akaike’s information criterion (AIC) value or mini-
mum residuals were selected. It should be noted that
subjects were only included if the number time-points
equals or are larger than the degree of the polynomials.
Therefore, with increasing degree of polynomials, the
size of the sub-population shrinks so not all polynomials
(subjects) were classified. However, a crude estimation
of the structure of the sub-populations were obtained.
The classification in two steps: 1) The Kullback-Leibler
divergence or relative entropy [21] were calculated for all
pairs of polynomials (equal to the number subjects in the
sub-populations conditional on the degree of the polyno-
mials above) with each subject in turn representing the
true distribution. The outcome is a n*n matrix holding all
the entropy values from the comparison of the polyno-
mial. The entropy is a measure of information in the data
sets such that the closer the polynomials are the smaller is
the entropy i.e. the smaller is the loss of information. 2)
The matrices (one for each clinical condition) were used
in k-means classification procedures (cluster.vq procedure
in scipy (http://scipy.org/); KMeans in sklearn.cluster from
scikit (http://scikit-learn.org/)) with increasing number of
classes. The k-means works by randomly selecting one or
more polynomials (subjects) in the entropy-list as cen-
troids and then clustering the polynomials with the lowest
divergence with or distance to the centroid. This were
done with 2500 seeds of centroids in each classification
procedure and a convergence threshold of 1*E-5 to avoid
local minima in the scipy k-means procedure. In the scikit
procedure 100,000 seeds were used. The iteration stopped
when one of the two criteria (threshold or number of
seeds) was reached first. The output is a code-book (list
of polynomials) belonging to the same cluster or class
for the best fit. This procedure were implemented for
increasing number of clusters (classes) and for
goodness-of-fit the Akaike information criteria AIC
were used to decide on the number of clusters (classes)
in the sub-population. The difference between succes-
sive classes AIC is chi-square distributed and when the
associated p-value was higher than the decreasing Bon-
feroni p-value (number of classes) the classification
procedure were stopped. The penultimate classification
was then defined as the optimal classification.
It is presumed and intended that the procedure gener-
ates homogeneous populations (which of course is an
over-simplification) and the time-series where therefore
collated in one composite time-series for each class. The
classes where then evaluated within a sub-population (to
confirm the separation of classes) and between sub-
populations (diabetics and non-diabetics) using the
Kolmogorov-Smirnov two-sample test as described above.
Statistics
All statistics were done using the numpy and scipy pack-
ages available from SciPy.org on the Ubuntu 14.04 LTS
Linux platform coded in Python using the Spyder 2.2.5
interpreter under the terms of the MIT License. Power
calculations were done using the power_t_test algorithm
from The Comprehensive R Archive Network (CRAN,
The R Foundation for Statistical Computing) using the
rpy2 Python interface. All the software are open source
and freely available.
Results
General description of the data
The basic data for the included patients is shown in
Table 1. The majority of the patients were females
(71.5 %), but sex distribution differs significantly be-
tween non- diabetics and diabetics, where the two gen-
ders were equally represented in the last group. Thirty
percent of the patients were classified as diabetics, when
both categories of diabetics were included. The age at
surgery was significantly lower in the non-diabetic group
(NDM) group compare to the two diabetic groups.
Almost half of the glycaemic diabetics, DMT2, turned
non-diabetics after surgery, NDM, (DMT2-NDM sub-
population) to which may be added the 17 patients re-
ceiving post-surgery (but not pre-surgery) anti-diabetic
treatment. This number may be even higher as the 34
patients still diabetics (DMT2-DMT2) according to the
HbA1c levels may have shorter follow-up times and with
time and weight loss may actually convert to a non-
diabetic state. The average time for conversion in this
group was 202 days (range 42 to 708 days) as judged
from the HbA1c levels. Notably, this observation may, at
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least in part, be explained by the half-life of HbA1c and
time span between outpatient visits, since weight loss is
ongoing the first 1–2 years after RYGB. The fate of the
treatment DM group differs from the glycaemic DM
group: the time to NDM-conversion was shorter and
more than 91 % did convert to NDM post-surgery, while
only 65 % converted in the glycaemic DM group (includ-
ing the 17 subjects prescribed anti-diabetic treatment
post-surgery, Table 1). The post-surgery NDM status in
this group was defined as HbA1cIFCC values below 48
Table 1 Clinical status. Age at surgery and time to post-surgery non-diabetic state for pre-surgery diabetic subjects
Diabetics (DM) 223
By glycemic status 100
NDM post surgery 48
DMT2 post surgery 34
NDM post/treat DMT2 17 (see text)
By treatment only 123
NDM post surgery 112
DMT2 post surgery 11
Non-diabetics (NDM) 518
Not determined glycemic 5





Age at surgery Glycemic DMT2 Treatment DMT2 NDM
Females Males Females % Females Males Females % Females Males Females %
Number 54 46 54.0 % 70 53 56.9 % 402 116 77.6 %
Mean 49.58 50.31 48.55 48.5 41.97 41.02
Minimum 30.79 30.29 27.08 27.49 18.97 19.05
Maximum 64.65 65.53 61.95 61.83 65.37 59.18
Variance 71.66 50.14 77.68 69.14 91.38 83.39
Std 8.47 7.08 8.81 8.31 9.56 9.13
Females-Males. p-value* 0.642 0.975 0.33




Days to NDM after surgery Glycemic DMT2 Treatment DMT2
Females Males Females Males
Number 33 32 59 41
Mean 202.55 201.94 146.64 178.61
Minimum 42 84 11 66
Maximum 708 696 451 751
Variance 21040 18975 8088 23356
Std 145 137 90 153
Females-Males. p-value 0.986 0.239
Glycemic DMT2 refers to patients classified as diabetics if HbA1c exceeds 48 mmol/mol regardless of any treatment. The Treatment DMT2 sub-population includes
all subjects with HbA1c below 48 mmol/mol but received antidiabetic medical treatment (drugs or insulin)
*The p-values are given as nominal values. Only p-values <0.001 can be considered significant after Bonferoni correction for multiple testing
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and medical treatment withdrawn. There were no differ-
ences between genders within each sub-population.
The actual diabetic status of the treatment DM group
was not unambiguously defined and for some variables
this group was similar to the glycaemic DM groups, in
others to the NDM group (see also Additional file 1:
Table S1). Therefore the treatment DM group was not
further included in interpretation of the RYGB data.
All data for all the variables in each sub-population
are listed in Additional file 1: Table S1. An excerpt of
the primary outcome variables (HbA1c, insulin and glu-
cose) is tabulated in Table 2 (see also Additional file 2:
Table S2). The relative changes (pre- to post-surgery)
were significant for weight, BMI and the HbA1c measures
in all populations (NDM, DMT2-NDM and DMT2-
DMT2). The average weight loss and decrease in BMI
were approximately 25 %, but varies considerably from al-
most no decrease up to more than 50 %, suggesting very
heterogeneous sub-populations of weight loss responders.
The changes in the NDM and the DMT2-NDM sub-
populations were marginal significantly different for
weight and BMI for females but not for males.
The relative changes in HbA1c were significant except
for the DMT2-DMT2 females. Pre- to post-surgery
changes in HbA1c values differed significantly between the
NDM and DMT2-NDM sub-populations, and to a lesser
extent between the NDM and DMT2-DMT2, although the
values were highly variable. The difference of post-surgery
levels NDM and DMT2-NDM sub-populations compared
to DMT2-DMT2 is of course due to the classification cri-
teria (see Methods). The relative changes were 2.6 to 3.8
fold higher in the diabetic sub-populations than in the
non-diabetic sub-population, but nevertheless the change
in the NDM group was significant and the metabolic state
was “improved” in this otherwise non-diabetic sub-
population. The post-surgery levels of HbA1c in both the
diabetic groups approached pre-surgery but not the post-
surgery levels in the non-diabetics.
Insulin decreased 45–60 % post-surgery irrespective of
the pre-surgery levels and glucose tolerance, except for fe-
males in the DMT2-DMT2 sub-population (Additional
file 2: Table S2). There were no significant differences of
the relative changes in level between the sub-populations
and all post-surgery levels were within the normal range.
However, the pre-surgery levels showed a complex pat-
tern: the mean levels were increased in DMT2-NDM
sub-population and the male NMD sub-population, but
not in in the female NDM sub-population and in the
DMT2-DMT2 sub-populations (Table 2 and Additional
file 2: Table S2). Also, some subjects in the NDM sub-
populations had increased pre-surgery insulin levels,
suggesting that the metabolic steady state in the non-
diabetic subjects (as judge by the HbA1c levels) were
heterogeneous i.e. may be defined as pre-diabetics.
A similar pattern was observed for fasting glucose
levels with significant differences between pre- and post-
surgery levels and relative changes (8 % in the non-
diabetic sub-population up to 26 % in the DMT2-NDM
sub-populations, Additional file 2: Table S2). On average,
glucose levels were normalized in the NDM and DMT2-
NDM sub-populations, but not in the DMT2-DMT2
sub-population and some subjects did have persistent
hyperglycemia post-surgery in all sub-populations. Im-
portantly, the post-surgery level in diabetics did not
reach the pre-surgery level of the non-diabetics and not
at all the non-diabetic post-surgery level for at least
some of the subjects in the diabetic sub-populations.
The HOMA-beta and HOMA-IR indices decreased
53–60 % in the NDM sub-populations irrespective of
gender (Table 2). No significant changes were seen in
the diabetic sub-populations except for HOMA-IR in
the male DMT2-NDM sub-population (Additional file 3:
Table S3). The trends were however similar for HOMA-
IR in all sub-populations with a substantial increase in
insulin sensitivity. Importantly, the pre- and post-surgery
levels of HOMA-IR were significantly different compar-
ing NDM and DMT2-NDM (Table 2). The NDM and
DMT2-NDM sub-population had similar levels of
HOMA-beta values and seemed distinctively different
from the DMT2-DMT2 sub-population, but these differ-
ences did not reach statistical significance. It should be
noted that the number of subjects in the DMT2-DMT2
sub-population was low and variances rather high.
C-peptide decreased 34–44 % post-surgery with no dif-
ference in the NDM and DMT2-NDM sub-populations.
The decreases in post-surgery levels in the DMT2-DMT2
sub-population were notable, but did not reach signifi-
cance. The C-peptide levels were only marginal different
when the NDM and DMT2-NDM subpopulations were
compared (Additional file 2: Tables S2).
The changes in lipids were rather complex. Choles-
terol decreased 17–26 % after surgery in the NDM and
female DMT2-NDM sub-populations, and although sub-
stantial decreases were also seen in the DMT2-DMT2
sub-populations they did not reach significance. A simi-
lar pattern was seen for LDL-cholesterol. Triglyceride
and VLDL-cholesterol levels decreased substantially in
all sub-populations although the decreases were only
marginal in the DMT2-DMT2 sub-populations. Small
increases of HDL-cholesterol were detected. HDL-
cholesterol was within the normal range except for a few
subjects deviating slightly from the normal range.
The low-grade inflammatory parameter C-reactive pro-
tein decreased to a large extend in all sub-populations and
gender (56–79 %), although the changes did not reach sig-
nificance in the male DMT2-DMT2 sub-population. The
decrease was much less for leukocytes (14–25 %) but still
significant except for DMT2-DMT2 sub-populations.
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Table 2 Maximal changes in glucose-related variables
HBA1CIFCC (mmol/mol) Range <48
NDM DMT2-NDM DMT2-DMT2
Pre-surgery Pre-surgery Pre-surgery Post-surgery Pre-surgery Post-surgery
Number of subjects 179 47 8
Mean 37 32 63 38 84 53
Range 27–47 24–43 42–113 28–46 54–122 48–70
Comparison of conditions, p-values*
Pre-surgery Post-surgery
NDM v DMT2-NDM <0.001 <0.001
NDM v DMT2-DMT2 <0.001 <0.001
DMT2-NDM v DMT2-DMT2 0.031 <0.001
Glucose (mmol/L) Range 4.2–6.1
NDM DMT2-NDM DMT2-DMT2
Pre-surgery Post-surgery Pre-surgery Post-surgery Pre-surgery Post-surgery
Number of subjects 182 43 7
Mean 5.4 4.9 8.8 5.8 9.8 6.4
Range 3.9–8.0 1.3–7.1 3.3–24 4.1–9.1 3.4–19 4.8–8.4
Comparison of conditions, p-values
Pre-surgery Post-surgery
NDM v DMT2-NDM <0.001 <0.001
NDM v DMT2-DMT2 0.070 0.032
DMT2-NDM v DMT2-DMT2 0.647 0.323
Insulin (pmol/L) Range 10–125
NDM DMT2-NDM DMT2-DMT2
Pre-surgery Post-surgery Pre-surgery Post-surgery Pre-surgery Post-surgery
Number of subjects 177 42 7
Mean 113 41 150 50 69 32
Range 23–486 1–112 13–494 2–11 4–167 1–53
Comparison of conditions, p-values
Pre-surgery Post-surgery
NDM v DMT2-NDM 0.020 0.019
NDM v DMT2-DMT2 0.074 0.176
DMT2-NDM v DMT2-DMT2 0.007 0.022
HOMA-IR
NDM DMT2-NDM DMT2-DMT2
Pre-surgery Post-surgery Pre-surgery Post-surgery Pre-surgery Post-surgery
Number of subjects 175 42 7
Mean 28.1 9.5 59.1 13.5 36.8 9.3
Range 4.7–164.0 0.3–28.7 1.9–199.0 0.6–36.7 0.6–107.6 0.3–15.4
Comparison of conditions, p-values
Pre-surgery Post-surgery
NDM v DMT2-NDM <0.001 <0.001
Fenger et al. BMC Endocrine Disorders  (2016) 16:59 Page 6 of 10
With a few exceptions all subjects were within the normal
range for C-reactive protein and leukocytes.
A summary of the relative changes for all the variables
is shown in Additional file 3: Table S3. The significance
of the relative changes were high (p <0.001) for most of
the variables in the non-diabetic sub-population particu-
lar for women and with high power (>0.95). A similar
pattern was seen for the DMT2-NDM sub-population,
but important differences were observed. The most
striking observation was the high responsiveness of the
NDM sub-population to RYGB where many variables
were “normalized” compared to the DMT2-NDM sub-
populations and in particularly to the DMT2-DMT2
sub-populations in which only minor changes occurred
(the number of subjects is small and variances may be
large reducing the reliability of the statistics).
Trait distributions
The Kolmogorov-Smirnov analyses of similarity of trait
distributions are very complex. If a level of acceptance of
similarity is set at 0.05 then 311 similarities were ob-
served among all the patients. However, such a level
translates into low correlation. The more stringent level
of 0.9 reduced the number of similarity of two-trait dis-
tributions to 55 (44 unique) as shown in Additional file
4: Table S4. Only the weight-BMI association was ob-
served for all sub-populations. Taken all together, most
of the associations were consistent with the concept of
the metabolic syndrome including insulin, C-peptide,
lipids and inflammatory markers.
The comparison of trait distributions within gender
between the NDM and DMT2-NDM sub-populations
are shown in Additional file 5: Table S5. The similarity
p-values were significant for all traits in the female
population, but 13 traits in the male populations were
not significant. Except for the HOMA indices and TSH
significant differences were observed for in at least one
of the genders. Thus, the vast majority of trait distri-
butions do not emerge from a common distribution,
suggesting basic differences in metabolic physiology in
non-diabetics and diabetics even if the latter turned
non-diabetic after surgery.
Classification of sub-populations
The polynomial degree was 5 for non-diabetics and 4 for
the diabetic sub-populations (not shown). The classifica-
tion procedures detected five classes in an 8-class pro-
cedure in non-diabetics (NDM) where classes with less
than 5 polynomials (subjects) were ignored (Additional
file 6: Table S6). Eight of the ten comparisons were sig-
nificant. In all four classes may be discerned. Only two
different classes were detected in both the diabetic sub-
populations. The time courses of the classes for the non-
diabetics are plotted in Fig. 1.
In Table 3 the comparison of distributions between di-
abetics and non-diabetics are summarized. The analysis
was restricted to classes with 5 or more subjects. As the
comparison of the NDM classes 3 and 4 did not differ
and the comparison with the DMT2-DMT2 subpopul-
tions also did not differ significantly the number of dis-
tinctive classes in the entire population are 11.
Discussion
RYGB surgery is superior to medical treatment in optimiz-
ing glycemic control [22] and claimed in many studies to
resolve diabetes mellitus in most obese with diabetes. This
Table 2 Maximal changes in glucose-related variables (Continued)
NDM v DMT2-DMT2 0.564 0.925
DMT2-NDM v DMT2-DMT2 0.190 0.082
HOMA-BETA
NDM DMT2-NDM DMT2-DMT2
Pre-surgery Post-surgery Pre-surgery Post-surgery Pre-surgery Post-surgery
Number of subjects 174 41 6
Mean 1303 489 869 430 239 261
Range 236–5215 40–2072 113–1101 8–1184 88–369 121–546
Comparison of conditions, p-values
Pre-surgery Post-surgery
NDM v DMT2-NDM 0.023 0.204
NDM v DMT2-DMT2 <0.001 0.020
DMT2-NDM v DMT2-DMT2 0.001 0.063
Subjects were only included if both pre- and post-surgery values were available
NDM, glycemic non-diabetics pre- and post-surgery
DMT2-NDM; pre-surgery glycemic diabetics, post-surgery glycemic non-diabetics
*The p-values are given as nominal values. Only p-values <0.001 can be considered significant after Bonferoni correction for multiple testing
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is, however, not exactly true as RYGB defines a new
metabolic and physiological framework (see also [23]).
First, HbA1c and glucose levels in the diabetics did just
barely reach the pre-surgery levels in the non-diabetic,
but certainly did not approach the post-surgery levels
of the non-diabetics. This is particularly the case for
the diabetic sub-population that apparently turned
non-diabetic after surgery, i.e. they did not become true
non-diabetics. Second, the distributions of the traits
differed markedly between and within sub-populations.
Third, at least 11 classes or sub-populations are present
in the entire study population each representing differ-
ent physiological statuses. This is particularly apparent
when the NDM and the DMT2-DMT2 sub-populations
were evaluated, but importantly also when NDM and
the DMT2-NDM sub-populations were compared. Al-
though several variables were or became normalized
after surgery the control population is not the usual
non-treated matches but rather the non-diabetic RYGB
population, and hence a new physiological set-point is de-
fined. Thus, the diabetics stayed diabetics. It should be
noted that even in the non-diabetic sub-population gross
deviations of e.g. insulin is seen, that is the non-diabetic
sub-population may in fact not be that non-diabetic.
The actual important physiological changes resulting
after RYGB or other bariatric procedures are unclear
[15, 24]. Lack of a universal definition of remission of
diabetes [3], different study designs and small popula-
tions have hampered our understanding of the RYGB
influence on the glycaemic state. An important question
is whether weight-independent effects on the glycaemic
state are present. Some studies ascribe the glycaemic im-
provement to the weight loss [12, 14], but another study
showed that weight gain that occurred in ~1/3 of the di-
abetics two years after RYGB did not influence the im-
provement in peripheral or hepatic insulin sensitivity
[25]. In addition, the improvement of glycaemic status
shortly after surgery without weight loss has been shown
Fig. 1 Trajectories of the five clusters (out of 8) containing five or
more subjects. The data was pooled for all the subjects in the clusters
increasing the number data points to no less than 40, i.e. 148 subjects
and not less than 750 measurements were included in the analysis.
Here the trajectories for the non-diabetic sub-populations are shown.
The red dot indicates the point of normalization of BMI at time zero i.e.
the penultimate data points before surgery. Although the trajectories
seem alike most of them differed significantly. See Additional file 6:
Table S6 for statistical data for the clusters for all sub-populations
(including the diabetic sub-populations)
Table 3 Comparison of clinical conditions
NDM v DMT2-NDM
DMT2-NDM
Class number 1 2 Total
Subjects 6 12 18
NDM
1 46 <0.01* <0.01
2 69 <0.01 <0.01
3 8 0.03 0,25
4 8 0.09 0.10




Class number 1 2 Total
Subjects 17 7 24
NDM
1 46 <0.01 <0.01
2 69 <0.01 <0.01
3 8 <0.01 0,95
4 8 <0.01 1.00




Class number 1 2 Total
Subjects 17 7 24
DMT2-NDM
1 6 <0.01 0.21
2 12 0.21 0.08
Total 18
The clusters or classes should contain at least 5 subjects to be included in
the analysis
NDM, glycemic non-diabetics pre- and post-surgery
DMT2-NDM; pre-surgery glycemic diabetics, post-surgery
glycemic non-diabetics
DMT2-DMT2; pre-surgery glycemic diabetics, post-surgery glycemic diabetics
*The p-values are given as nominal values. Only p-values <0.01 can be
considered significant after Bonferoni correction for multiple testing
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in several studies [8], although the effect of calorie re-
strictions cannot be ruled out in these studies [12, 13].
On the other hand it is widely accepted that peripheral
improvement of insulin sensitivity requires a moderate
to substantial weight loss [13, 14] at least to settle the
improvement, as later weight gain 1–2 years post-
surgery did not deteriorate the metabolic improvement
obtained [21].
The metabolic blueprint is residing in the genome as
complex networks of interacting genes and regulatory
structures [18, 26]. Myriads of polymorphisms and mu-
tations have been detected, not the least due to the ex-
plosion of massive sequencing. Thus, variations in
genetic structures translates into variations of genetic
networks and hence the expressed phenotypes. The
11sub-populations detected in the present study only
represent a tiny fraction of the unknown real number of
(homogeneous) sub-populations. The simple procedures
here applied to time-series data are insufficient to define
exact phenotypes. Structural equation modelling com-
bined with latent profiling and transfer entropy analysis
will provide an avenue to refinement in phenotype ana-
lysis and definition [18, 27, 28]. The precise definition of
the phenotypes is at the heart of a subsequent genetic
analysis, if such an analysis should have any hope of de-
fining just the important parts of the networks govern-
ing the metabolism.
Conclusions
Gastric bypass (RYGB) defines a new metabolic and
physiological framework that as a consequence requires
a redefinition of the diabetic status after gastric bypass
surgery. Hence, adapting the non-diabetics glycemic sta-
tus post-surgery as a reference the diabetics stayed dia-
betic although some (but not all) diabetics would be
classified as non-diabetics according to the usual refer-
ence values and levels. The significance of this is not
clear and is complicated by the heterogeneity of the
population. This heterogeneity can be envisioned as a
continuous distribution of physiological states deter-
mined by genetic and environmental factors [18], which
in turn will determine the consequences if any of the
new metabolic state of the obese subjects.
Additional files
Additional file 1: Table S1. Maximal changes in variables and the day
after RYGB. Values and summary statistics of all variables analysed before
and after gastric bypass for the subpopulations non-diabetics, diabetics
turned non-diabetics post-surgery and diabetics that stayed diabetics
post-surgery. Values and statistics are given for female and males,
respectively. (XLS 226 kb)
Additional file 2: Table S2. Maximal changes in glucose-related variables.
Values and summary statistics for glucose-related variables and diabetes for
both gender combined. An excerpt of the table of the central variables
related to diabetes is presented in Table 2. (XLS 48 kb)
Additional file 3: Table S3. Relative changes in variables after RYGB. The
changes in all traits are calculated as fraction relative to pre-surgery
values for non-diabetics and diabetics turned non-diabetics, respectively.
The changes and significance are calculated for female and males
separately. (XLS 28 kb)
Additional file 4: Table S4. Komogorov-Smirnoff test for equality of
distributions of traits. Traits are pair-wise tested for distributional similarity
of the time-evolving changes in trait values (trajectories), that is to which
extent the traits may be correlated. The comparisons of distributions are
done for all subpopulations and gender separately. (XLS 22 kb)
Additional file 5: Table S5. Komogorov-Smirnoff test for equality of
distributions of traits between NDM and DMT2-NDM. Traits are tested for
distributional similarity between the non-diabetic subpopulation and the
diabetic turned non-diabetic subpopulation. (XLS 22 kb)
Additional file 6: Table S6. Clustering summary using the scikit k-means
procedure. The three subpopulations non-diabetics, diabetics turned
non-diabetics and diabetics staying diabetics after gastric bypass were
partitioned into subpopulations using the k-mean procedure for changes
in body mass index (BMI) during time. In all, at least 11 subpopulations
were identified. (XLS 21 kb)
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